Myrcludex B is tested in the treatment of HDV - the most severe form of viral hepatitis without current satisfactory treatment options 120 subjects were enrolled into MYR 202, making it the world’s largest HDV clinical study
“The positive results of the active therapy phase of this study were already presented at the AASLD meeting in Washington, DC in October 2017,” said Alexander Alexandrov, MD, Chief Medical Officer of MYR Pharma. “The follow-up phase of this study is now completed. This is a very important milestone in the development of Myrcludex B under the PRIME scheme in Europe,” he added.
“We appreciate that the EASL annual meeting organizers recognize the significance of the HDV medical problem and the importance of the results of this so far largest study with a novel compound in hepatitis Delta”, said Heiner Wedemeyer, MD, Professor at Essen University Hospital and Chairman of MYR Pharma’s Clinical Advisory Board.
About Myrcludex B
Myrcludex B is a first-in-class entry inhibitor for the treatment of chronic hepatitis B (HBV) and its co-infection hepatitis Delta. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver. The drug has received Orphan Designation for treatment of HDV infection from the EMA and FDA, and PRIME scheme eligibility from the EMA.
To find out more about Myrcludex B, visit http://myr-pharma.com/science/about-myrcludex-b.
About MYR Pharma
MYR Pharma GmbH is a German clinical stage biotechnology company focused on the development of drugs for the treatment of chronic hepatitis B and Delta virus infections. For more information, please visit http://myr-pharma.com.
Contact: Alexey Eliseev, 1-617-953-0767
View original content: http://www.prnewswire.com/news-releases/myr-pharma-completes-clinical-trial-of-myrcludex-b-in-chronic-hepatitis-delta-300612330.html
SOURCE MYR Pharma
